Our findings revealed a significant increase in the methylation of PDE2A in specific tumor tissues, such as KIRP, pheochromocytoma and paraganglioma (PCPG), PRAD, TGCT, and THCA. Here, PDE2A is linked to prostate adenocarcinoma.